Retrospective Study of Radio-induced Toxicities in the Treatment of Lung Cancer With Tomotherapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

318 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-05-01

Study Completion Date

2023-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Lung cancers treated by Tomotherapy represent between 60 and 100 patients per year at the CHR of Metz-Thionville. Some patients were observed to present acute toxicities during treatment such as dysphagia or esophagitis of CTCAE grade \> 2. Beyond well known therapeutic and comorbidities factors, the pathophysiology of these events is largely ruled by a constitutional factor - the enzymatic equipment allowing more or less good repair of the DNA lesions induced by radiotherapy (RT). This equipment is characteristic of each individual, hence the term individual radiosensitivity (IR).The scientific literature is rather poor in data describing the frequency of these toxicities in patients receiving RT for lung cancer.

The objective of this study is to describe the frequency of acute and late toxicities after normofractionated radiotherapy of 66 Gy in 33 fractions in patients with small cell or non-small cell lung cancer, stage 2 or 3.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cardiopulmonary Toxicity of Thoracic Radiotherapy

NCT03978377

Oesophageal Cancer Non Small Cell Lung Cancer

RECRUITING

Adaptive, Image-guided, Intensity-modulated Radiotherapy for Head and Neck Cancer in the Reduced Volumes of Elective Neck

NCT01287390

Primary Non-operated Squamous Cell Carcinoma of Oral Cavity Primary Non-operated Squamous Cell Carcinoma of Oropharynx Primary Non-operated Squamous Cell Carcinoma of Hypopharynx +1 more

COMPLETED PHASE2

Prospective Study on Factors Predicting Chemo-Radiotherapy Induced Pulmonary and Esophageal Injury

NCT00631839

Thoracic Neoplasms

UNKNOWN

Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer

NCT00471835

Lung Cancer

WITHDRAWN PHASE1/PHASE2

Study of Cryoablation for Metastatic Lung Tumors

NCT01957787

Neoplasm Metastasis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* stage II-III non-small cell or small cell lung cancer treated with normo-fractionated radiotherapy of 66Gy in 33 fractions using Tomotherapy

Exclusion Criteria

* patient who refused to be included in the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Xavier MICHEL, MD

Role: PRINCIPAL_INVESTIGATOR

CHR Metz Thionville Hopital de Mercy

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHR Metz-Thionville/Hopital de Mercy

Metz, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023-05Obs-CHRMT

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

TOMO Versus IMRT in Nasopharyngeal Carcinoma Patients

NCT03588403 UNKNOWN

Follow-up of Pulmonary Radiotoxicity for Bronchopulmonary Cancer.

NCT03931356 COMPLETED

Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously

NCT01543672 COMPLETED PHASE1/PHASE2

Stereotactic Volumetric Radiotherapy in Prostate Cancer

NCT02423889 COMPLETED PHASE2

Non-interventional Observational Study of Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Cancer

NCT02228356 UNKNOWN

Phase II Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Tumors of the Lung

NCT00832780 COMPLETED NA

Radiation-induced Cardiac Toxicity After Non-small Cell Lung Cancer Radiotherapy

NCT04867564 UNKNOWN

High-Dose 3-Dimensional Conformal Radiation Therapy in Treating Patients With Inoperable Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

NCT00062335 TERMINATED PHASE1

Stereotactic Body Radiotherapy and Radiofrequency Ablation for Lung Tumors Near Central Airways

NCT01051037 COMPLETED NA

Coagulation System In STereotactic Radiotherapy Of NSCLC

NCT03893461 UNKNOWN

Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00124618 COMPLETED PHASE2

Transbronchial Catheter Aspiration and Transbronchial Needle Aspiration in the Diagnosis of Lung Cancer

NCT00807391 COMPLETED NA

Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer

NCT01185639 COMPLETED NA

Protocol for Primary Fractionated Stereotactic Body Radiation Therapy for Stage T1 - T3N0 Non Small Cell Lung Carcinoma.

NCT00727350 UNKNOWN PHASE2

Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc)

NCT03548428 RECRUITING PHASE2

Stereotactic Body Radiotherapy for Head and Neck Tumors

NCT01344356 COMPLETED PHASE4

Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Metastatic Tumors to the Liver

NCT01030757 TERMINATED PHASE2

Thermal Ablation Combined With External Beam Radiation Therapy for Patients With Inoperable Non-Small Cell Lung Cancer > 3.5 cm in Size

NCT01028612 TERMINATED NA

Dose-painting Radiation for LA-NSCLC

NCT05031533 RECRUITING NA

Radiotherapy or Observation of Liver Metastases in Small Cell Lung Cancer

NCT05150145 RECRUITING NA

Carotid Artery Stenosis and Ischemic Cerebrovascular Events After Radiotherapy in Patients With Head and Neck Cancer

NCT06556979 COMPLETED

A Phase I/II Trial of Stereotactic Body Radiation Therapy

NCT00591838 COMPLETED PHASE1/PHASE2

Stereotactic Body Radio Therapy (SBRT) for Early-stage Non Small Cell Lung Cancer (NSCLC)

NCT00870116 UNKNOWN NA

Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

NCT00002577 COMPLETED PHASE1/PHASE2

Stereotactic Radiotherapy for Brain Metastases

NCT03286023 UNKNOWN